Circulating IGFBP-3 and Interleukin 6 As Predictors of Osteoporosis in Postmenopausal Women: A Cross-Sectional Study

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2023 Apr 10

PMID 37035758

Authors

Xiu Shi

Jingjing Jiang

Ru Hong

Feng Xu

Shouqian Dai

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the relationship between circulating IGFBP-3, IL-6, and bone mineral density and the potential diagnostic role of circulating IGFBP-3 and IL-6 in postmenopausal women with osteoporosis.

Methods: Eighty-five postmenopausal women at Soochow University's First Affiliated Hospital, Osteoporosis and Menopause Clinics, were recruited. Forty-five of 85 women were diagnosed with osteoporosis. Circulating IL-6, PTH, 1,25(OH)2D3, osteocalcin (OST), IGF-1, IGFBP-3, and bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) were measured in 40 ordinary and 45 osteoporotic women. A simple regression analysis calculated the correlation between age, BMD, IL-6, and IGFBP-3. Multiple stepwise regression analyses were conducted to determine which variables were independently related to BMD. The potential role of IGFBP-3 and IL-6 in the diagnosis of postmenopausal osteoporosis was predicted using the area under the receiver operating characteristic curve (ROC, AUC).

Results: Age, years since menopause, and circulating IL-6, PTH, and IGFBP-3 were significantly higher in the osteoporosis group compared to the normal group. Osteoporotic women had substantially lower BMDs of the LS and FN than normal women. Age-related increases were found for IGFBP-3 and IL-6, whereas age-related decreases were observed for LS/FN BMD. IGFBP-3 and IL-6 were both negatively correlated with LS and FN BMD. Stepwise multiple regression analysis showed that IGFBP-3 and IL-6 were strong predictors of BMD in postmenopausal women. AUC cut-off values (IGFBP-3: 3.65, IL-6: 0.205) were best evaluated for the diagnosis of postmenopausal women with osteoporosis, and the AUC for circulating IGFBP-3 and IL-6 were 0.706 (95% CI 0.594-0.818) and 0.685 (95% CI 0.571-0.798), respectively.

Conclusion: In this cross-sectional study of postmenopausal women, IGFBP-3 and IL-6 were negatively related to BMD. Circulating IGFBP-3 and IL-6 might be essential predictors of postmenopausal osteoporosis and can help predict osteoporotic fracture.

Citing Articles

Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case-Control Study.

Roomi A, Ali E, Nori W, Rahmah M Indian J Clin Biochem. 2025; 40(1):97-104.

PMID: 39835234 PMC: 11741977. DOI: 10.1007/s12291-023-01163-y.

In-silico analysis predicts disruption of normal angiogenesis as a causative factor in osteoporosis pathogenesis.

James R, Subramanyam K, Payva F, E A, Tv V, Sivaramakrishnan V BMC Genom Data. 2024; 25(1):85.

PMID: 39379846 PMC: 11460074. DOI: 10.1186/s12863-024-01269-z.

The causal role of circulating inflammatory markers in osteoporosis: a bidirectional Mendelian randomized study.

Dong Q, Wu J, Zhang H, Luo L, Wu W Front Immunol. 2024; 15:1412298.

PMID: 39091505 PMC: 11291241. DOI: 10.3389/fimmu.2024.1412298.

Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review.

Orsini F, Crotti C, Cincinelli G, Di Taranto R, Amati A, Ferrito M Biology (Basel). 2023; 12(10).

PMID: 37887030 PMC: 10604370. DOI: 10.3390/biology12101320.

References

Rossi L, Copes R, Dal Osto L, Flores C, Comim F, Premaor M . Factors related with osteoporosis treatment in postmenopausal women. Medicine (Baltimore). 2018; 97(28):e11524. PMC: 6076108. DOI: 10.1097/MD.0000000000011524. View

Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397(6717):315-23. DOI: 10.1038/16852. View

Zheng S, Vrindts Y, Lopez M, De Groote D, Zangerle P, Collette J . Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997; 26(1):63-71. DOI: 10.1016/s0378-5122(96)01080-8. View

Govoni K, Baylink D, Mohan S . The multi-functional role of insulin-like growth factor binding proteins in bone. Pediatr Nephrol. 2004; 20(3):261-8. PMC: 2923924. DOI: 10.1007/s00467-004-1658-y. View

Wang S, Moerman E, Jones R, Thweatt R, Goldstein S . Characterization of IGFBP-3, PAI-1 and SPARC mRNA expression in senescent fibroblasts. Mech Ageing Dev. 1996; 92(2-3):121-32. DOI: 10.1016/s0047-6374(96)01814-3. View

Eguchi K, Akiba Y, Akiba N, Nagasawa M, Cooper L, Uoshima K . Insulin-like growth factor binding Protein-3 suppresses osteoblast differentiation via bone morphogenetic protein-2. Biochem Biophys Res Commun. 2018; 507(1-4):465-470. DOI: 10.1016/j.bbrc.2018.11.065. View

Adebanjo O, Moonga B, Yamate T, Sun L, Minkin C, Abe E . Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol. 1998; 142(5):1347-56. PMC: 2149353. DOI: 10.1083/jcb.142.5.1347. View

Kanis J, Melton 3rd L, Christiansen C, JOHNSTON C, Khaltaev N . The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9(8):1137-41. DOI: 10.1002/jbmr.5650090802. View

Gao M, Zhu B, Xu Z, Liu S, Liu J, Zhang G . Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene. BMC Med Genet. 2018; 19(1):182. PMC: 6173921. DOI: 10.1186/s12881-018-0698-2. View

10.

Alghadir A, Aly F, Gabr S . Effect of Moderate Aerobic Training on Bone Metabolism Indices among Adult Humans. Pak J Med Sci. 2014; 30(4):840-4. PMC: 4121709. DOI: 10.12669/pjms.304.4624. View

11.

Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K . Age-dependent changes in body composition in postmenopausal Japanese women: relationship to growth hormone secretion as well as serum levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Eur J Endocrinol. 1998; 138(6):633-9. DOI: 10.1530/eje.0.1380633. View

12.

. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021; 28(9):973-997. DOI: 10.1097/GME.0000000000001831. View

13.

De Benedetti F, Pignatti P, Vivarelli M, Meazza C, Ciliberto G, Savino R . In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J Immunol. 2001; 166(7):4334-40. DOI: 10.4049/jimmunol.166.7.4334. View

14.

Abdolalipour S, Mirghafourvand M . Effect of Education on Preventive Behaviors of Osteoporosis in Adolescents: A Systematic Review and Meta-Analysis. Int Q Community Health Educ. 2020; 41(3):325-347. DOI: 10.1177/0272684X20936833. View

15.

Mancini A, Vergani E, Bruno C, Barini A, Silvestrini A, Meucci E . Relationships Between Thyroid Hormones, Insulin-Like Growth Factor-1 and Antioxidant Levels in Hypothalamic Amenorrhea and Impact on Bone Metabolism. Horm Metab Res. 2019; 51(5):302-308. DOI: 10.1055/a-0859-4285. View

16.

Latourte A, Cherifi C, Maillet J, Ea H, Bouaziz W, Funck-Brentano T . Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann Rheum Dis. 2016; 76(4):748-755. DOI: 10.1136/annrheumdis-2016-209757. View

17.

Alghadir A, Gabr S, Al-Eisa E, Alghadir M . Correlation between bone mineral density and serum trace elements in response to supervised aerobic training in older adults. Clin Interv Aging. 2016; 11:265-73. PMC: 4778779. DOI: 10.2147/CIA.S100566. View

18.

Ranke M . Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract Res Clin Endocrinol Metab. 2015; 29(5):701-11. DOI: 10.1016/j.beem.2015.06.003. View

19.

Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K . Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol (Oxf). 2000; 51(6):715-24. DOI: 10.1046/j.1365-2265.1999.00867.x. View

20.

Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H . HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A. 2013; 110(41):16568-73. PMC: 3799362. DOI: 10.1073/pnas.1308755110. View